💡 Snel antwoord
Etibo is lapatinib 250 mg, een dual HER2/EGFR tyrosine kinase inhibitor for advanced or metastatic HER2-positive breast cancer. Oral once-daily therapy combined with capecitabine or other regimens, usually after trastuzumab (Herceptin) failure. Significant side effects include diarrhoea, rash, and cardiotoxicity; requires close oncologist supervision and ECG monitoring.
📦 Elke bestelling is gedekt door onze Reshipment Assurance Policy — als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.
Waarom bestellen bij MedsBase
Onze generieke medicijnen zijn afkomstig van WHO-GMP gecertificeerde fabrikanten en worden wereldwijd verzonden in discrete, eenvoudige verpakkingen — geen medicijnnaam op de buitenkant van het pakket. Betalingen met kaart worden verwerkt via een gereguleerde processor (betalingsoverzichten vermelden een gereguleerde kaartbetalingprocessor — nooit “MedsBase” of een medicijnnaam). Crypto en SEPA bankoverschrijvingen worden ook geaccepteerd. Elke bestelling wordt ondersteund door ons Reshipment Assurance Policy.
What Is Etibo?
Etibo is a branded generic of lapatinib 250 mg, a small-molecule tyrosine kinase inhibitor that targets HER2 (ErbB2) en EGFR (ErbB1). Lapatinib blocks intracellular signaling downstream of these receptors, halting proliferation of HER2-positive cancer cells. Manufactured by Natco Pharma.
Critical: Lapatinib is an oncology drug used only under specialist supervision. It is not a general women’s health product. Use strictly according to oncologist protocol — typically after trastuzumab resistance develops.
Genitale herpes (eerste episode):
- Advanced/metastatic HER2+ breast cancer: 1250 mg daily (5 tablets) + capecitabine — after trastuzumab failure.
- HER2+ breast cancer with letrozole in postmenopausal women with ER+/HER2+ metastatic disease.
- Not indicated for adjuvant (early-stage curative) therapy — trastuzumab ± pertuzumab remain standard there.
Hoe in te nemen
- Neem 1250 mg (5 tablets) once daily, at least 1 hour before or after food. Food significantly increases absorption and shifts dosing parameters; consistency matters.
- Typical partner drug: capecitabine 2000 mg/m²/day on days 1–14 of a 21-day cycle.
- ECG and LVEF monitoring at baseline and every 3 months (cardiotoxicity risk).
- Manage diarrhoea proactively — often grade 1–3, common in first cycle. Loperamide, hydration, dose reduction as needed.
- Avoid grapefruit, Seville oranges, and CYP3A4 inhibitors/inducers.
Bijwerkingen
Zeer vaak voorkomend: diarrhoea (60–80%), rash (40–60%), nausea, vomiting, fatigue, hand-foot syndrome, palmar-plantar erythrodysesthesia (with capecitabine combo).
Significant: hepatotoxicity (monitor LFTs), cardiotoxicity / reduced LVEF (5–6%), QT prolongation, interstitial lung disease (rare but serious).
Serious: severe liver injury, heart failure, severe skin reactions (Stevens-Johnson), pulmonary toxicity.
Who Should Not Take Etibo
- HER2-negative breast cancer (ineffective)
- Ernstige leverfunctiestoornis
- Symptomatic heart failure or severe cardiac dysfunction
- Pregnancy — teratogenic
- Concurrent strong CYP3A4 inhibitors or inducers without dose adjustment
Geneesmiddelinteracties
- Sterke CYP3A4-remmers (ketoconazole, ritonavir, clarithromycin, grapefruit): raise lapatinib levels significantly.
- Strong CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, St John’s Wort): reduce lapatinib levels and efficacy.
- PPIs, H2 blockers: reduce absorption — avoid or space by hours.
- Warfarin, digoxin: may increase levels.
Opslag
Store at room temperature (15–30 °C), away from moisture. Keep in original packaging. Keep out of reach of children.
Veelgestelde vragen
When is lapatinib used?
Advanced/metastatic HER2-positive breast cancer, typically after trastuzumab (Herceptin) resistance. Not used for early-stage curative therapy.
Why take on empty stomach?
Food increases lapatinib absorption 4–5×, making dosing unpredictable. Standard is consistent fasting — 1 hour before or after food — at a fixed time each day.
How bad is the diarrhoea?
Common, often grade 1–2; manageable with loperamide and hydration. Grade 3+ diarrhoea may require treatment interruption and dose reduction. Report early.
Will lapatinib damage my heart?
About 5–6% of patients have asymptomatic LVEF drops. ECG + echocardiogram at baseline and every 3 months. Usually reversible on dose adjustment or interruption.
Can I take lapatinib with trastuzumab?
Combination lapatinib + trastuzumab is used in specific protocols. Not routine without oncologist supervision.
What about fertility?
Effective contraception required during treatment and for 1 week after (teratogenic). Men should use effective contraception during and 3 months after.
Why is this in the Women's Health category?
HER2+ breast cancer disproportionately affects women (though rarely men get HER2+ breast cancer). Categorisation reflects the population, not a strict clinical cluster.
Is lapatinib still first-line?
For second-line HER2+ metastatic disease (after trastuzumab), lapatinib + capecitabine was standard for years. Newer options (T-DM1/Kadcyla, T-DXd/Enhertu, tucatinib) have since largely supplanted it in first-world oncology — lapatinib remains important where newer agents are unavailable.
Related Women’s Health Products
- Tamodex (Tamoxifen 10 mg)
- Tamilong (Tamoxifen 20 mg)
- Letroheal (Letrozole 2.5 mg)
- Duphaston (Dydrogesterone 10 mg)
- Deviry (Medroxyprogesterone 10 mg)
- Naprosyn (Naproxen 250 mg)
- Candid-V Gel (Clotrimazole)
⚕️ Medische disclaimer: Information is educational and does not replace medical advice. Consult a clinician before starting, stopping, or changing any medication, particularly for cancer therapy, hormonal treatments, and prescription products.
Gerelateerde alternatieven
Other oncology medications stocked alongside this product:

























Beoordelingen
Er zijn nog geen beoordelingen